Oricell Therapeutics Holdings Limited, a clinical-stage biotechnology company focused on cancer immunotherapies, announced the closing of a pre-IPO financing round exceeding $110 million to support global expansion and accelerate development of its CAR-T therapy pipeline.

The round was co-led by Vivo Capital, Beijing Medical and Health Care Industry Investment Fund, Qiming Venture Partners, and a leading global healthcare fund. Additional participants included an international sovereign wealth fund, E-Town Capital, Luxin Venture Capital, NGS Super, Elikon Investment, and Talon Capital.

The company said proceeds from the financing will be used to advance clinical programs, expand globally, and enhance its technology platforms as it prepares for future capital markets milestones.

Oricell is developing next-generation CAR-T therapies targeting both solid tumors and hematologic malignancies, an area widely considered one of the most challenging frontiers in oncology. Its platform combines three proprietary technologies: Ori®Ab for antibody discovery and engineering, Ori®Armoring for functional T-cell enhancement, and OnGo CMC for rapid manufacturing.

The company’s lead candidate, Ori-C101, targets GPC3 for the treatment of advanced hepatocellular carcinoma. The therapy has already completed investigator-initiated trials and a registrational Phase 1 study, demonstrating strong efficacy and safety data presented at major industry forums such as the ASCO Annual Meeting. Oricell is now preparing the program for pivotal trials, with the potential to become the first globally approved CAR-T therapy for hepatocellular carcinoma.

Beyond Ori-C101, Oricell is advancing a broader pipeline that includes secreted CAR-T, rapid-production CAR-T, and in vivo CAR-T programs aimed at improving accessibility and effectiveness of cell therapies.

The company also highlighted progress with OriCAR-017, another core asset that has achieved regulatory milestones including IND approvals in both China and the United States, as well as FDA Orphan Drug and Fast Track designations. Clinical data for the program has been featured at major conferences and published in leading medical journals, reinforcing Oricell’s capabilities in global clinical development and regulatory strategy.

KEY QUOTES:

“This financing is a testament to the global potential of our science and the dedication of our team. As we approach key inflection points in our clinical programs, our priority is clear: expedite the global development of our core assets and deepening our research into revolutionary technologies, including in vivo CAR-T and solid tumor CAR-T. We are committed to delivering transformative therapies that offer real hope to cancer patients worldwide, positioning Oricell as a dominant force in the global immunotherapy arena.”

Huanfeng Yang, Chairman and CEO, Oricell Therapeutics

“While cell therapy is undoubtedly the future of oncology, solid tumors remain the industry’s toughest nut to crack. Oricell distinguishes itself not just through best-in-class clinical data for its GPC3 CAR-T, but also through a pragmatic and visionary roadmap for next-generation modalities like in vivo CAR-T. We have high conviction in their integrated ‘Platform and Pipeline’ strategy and believe they are poised to set the new standard of care in the field. Vivo Capital is eager to deploy our global network to accelerate Oricell’s expansion into international markets.”

Shan Fu, Managing Partner, Vivo Capital

“As an early investor that has stood with Oricell since the Pre-A round, we have witnessed every milestone of its journey, from technological exploration to pipeline realization, and from local innovation to global expansion. We look forward to Oricell leveraging breakthrough cell therapy solutions and stronger clinical data to define the next generation of cancer care, bringing hope to patients worldwide.”

William Hu, Managing Partner, Qiming Venture Partners